AIM: To investigate the expression of p28/gankyrin gene and its role in the carcinogenetic process of human hepatocellular carcinoma (HCC). METHODS: 64 specimens of HCC and para-carcinoma tissues, 22 specimens of non-tumor liver tissues (7 normal, 15 cirrhosis), 10 specimens of normal human tissues and 5 hepatoma cell lines were studied for the expression of p28/gankyrin by Northern blot. The expression of p28/gankyrin protein was detected immunohistochemically by using the specific polyclonal antibody. RESULTS: Northern blot analysis indicated that the expression of p28/gankyrin mRNA was intensively distributed in brain and heart, weakly in lung, spleen and muscle, undetectable in digestive system including liver, pancreas, stomach, small and large intestines. p28/gankyrin mRNA was absent in normal liver, weakly detected in liver cirrhosis and in 18 of 64 para-carcinoma liver tissues. In contrast, the expression of p28/gankyrin mRNA was intensively detected in all 5 hepatoma cell lines tested, markedly increased in 57 of 64 and moderately increased in 5 of 64 HCC samples. In comparison with liver cirrhosis and para-carcinoma liver tissues, the average expression of p28/gankyrin mRNA in HCC was increased 3.6- (2.901+/-0.507 vs 0.805+/-0.252, P<0.05) and 5.2-fold (2.901+/-0.507 vs 0.557+/-0.203, P<0.01), respectively. In addition, p28/gankyrin mRNA expression level was higher in HCC with portal vein tumor thrombus and microscopic hepatic vein involvement (P=0.021 and P=0.047, respectively). The overexpression of p28/gankyrin protein in HCC was targeted in hepatic tumor cells, not in bile duct cells and other interstitial cells. CONCLUSION: Overexpression of p28/gankyrin in HCC plays an important role and contributes to the metastasis potential in the process of carcinogenesis. p28/gankyrin may become a specific biological tissue marker for the pathological diagnosis of HCC.
AIM: To investigate the expression of p28/gankyrin gene and its role in the carcinogenetic process of humanhepatocellular carcinoma (HCC). METHODS: 64 specimens of HCC and para-carcinoma tissues, 22 specimens of non-tumor liver tissues (7 normal, 15 cirrhosis), 10 specimens of normal human tissues and 5 hepatoma cell lines were studied for the expression of p28/gankyrin by Northern blot. The expression of p28/gankyrin protein was detected immunohistochemically by using the specific polyclonal antibody. RESULTS: Northern blot analysis indicated that the expression of p28/gankyrin mRNA was intensively distributed in brain and heart, weakly in lung, spleen and muscle, undetectable in digestive system including liver, pancreas, stomach, small and large intestines. p28/gankyrin mRNA was absent in normal liver, weakly detected in liver cirrhosis and in 18 of 64 para-carcinoma liver tissues. In contrast, the expression of p28/gankyrin mRNA was intensively detected in all 5 hepatoma cell lines tested, markedly increased in 57 of 64 and moderately increased in 5 of 64 HCC samples. In comparison with liver cirrhosis and para-carcinoma liver tissues, the average expression of p28/gankyrin mRNA in HCC was increased 3.6- (2.901+/-0.507 vs 0.805+/-0.252, P<0.05) and 5.2-fold (2.901+/-0.507 vs 0.557+/-0.203, P<0.01), respectively. In addition, p28/gankyrin mRNA expression level was higher in HCC with portal vein tumor thrombus and microscopic hepatic vein involvement (P=0.021 and P=0.047, respectively). The overexpression of p28/gankyrin protein in HCC was targeted in hepatic tumor cells, not in bile duct cells and other interstitial cells. CONCLUSION: Overexpression of p28/gankyrin in HCC plays an important role and contributes to the metastasis potential in the process of carcinogenesis. p28/gankyrin may become a specific biological tissue marker for the pathological diagnosis of HCC.
Authors: H Higashitsuji; K Itoh; T Nagao; S Dawson; K Nonoguchi; T Kido; R J Mayer; S Arii; J Fujita Journal: Nat Med Date: 2000-01 Impact factor: 53.440
Authors: C T Liew; H M Li; K W Lo; C K Leow; J Y Chan; L Y Hin; W Y Lau; P B Lai; B K Lim; J Huang; W T Leung; S Wu; J C Lee Journal: Oncogene Date: 1999-01-21 Impact factor: 9.867
Authors: Yu Wang; Han Chong Toh; Pierce Chow; Alexander Y F Chung; David J Meyers; Philip A Cole; London L P J Ooi; Caroline G L Lee Journal: FASEB J Date: 2012-03-29 Impact factor: 5.191
Authors: Annesa Flentje; Kord M Kober; Adam W Carrico; Torsten B Neilands; Elena Flowers; Nicholas C Heck; Bradley E Aouizerat Journal: Brain Behav Immun Date: 2018-03-13 Impact factor: 7.217
Authors: Anjali Mahajan; Yi Guo; Chunhua Yuan; Christopher M Weghorst; Ming-Daw Tsai; Junan Li Journal: J Mol Biol Date: 2007-08-22 Impact factor: 5.469